Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 16/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SIK1 | P57059 | 1/20 | 0.39 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262039 | 0.89 | FGFR1 (0.49) | FGFR1FGFR4SIK2CSF1RSIK1 | |
| SCHEMBL30261990 | 0.86 | FGFR1 (0.73) | FGFR1FGFR4CSF1RFGFR2FGFR3 | |
| SCHEMBL15434048 | 0.81 | FGFR1 (0.73) | FGFR1FGFR4SIK2CSF1RSIK1 | |
| SCHEMBL30261966 | 0.80 | FGFR4 (0.43) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL30261967 | 0.74 | FGFR4 (0.73) | FGFR4FGFR2 | |
| SCHEMBL30262058 | 0.73 | FGFR1 (0.85) | FGFR1FGFR4CSF1RFGFR2FGFR3 | |
| SCHEMBL30262007 | 0.72 | FGFR4 (0.71) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL30262053 | 0.70 | FGFR1 (0.76) | FGFR1FGFR4CSF1RFGFR2FGFR3 | |
| SCHEMBL15434047 | 0.70 | FGFR1 (0.68) | FGFR1FGFR4SIK2CSF1RSIK1 | |
| SCHEMBL30261946 | 0.70 | FGFR1 (0.75) | FGFR1FGFR4CSF1RFGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023039828-A1 | FUSED RING COMPOUNDS AS INHIBITORS OF FGFR4 TYROSINE KINASES | NUTSHELL BIOTECH (SHANGHAI) CO., LTD. (CN) | 2023-03-23 | — | — | WO | disclosed |